Efficacy of zoledronic acid infusion on bone mineral density among adult population
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20195805Keywords:
Bisphosphonates, Bone mineral density, Osteopenia, Osteoporosis, T score, zoledronic acidAbstract
Background: Osteoporosis is a skeletal disease characterised by impaired bone strength due to reduced bone mineral density. As a consequence, patients with osteoporosis are at increased risk of fractures. Zoledronic acid is an anti-resorptive agent that acts by slowing down osteoclast medicated bone resorption, thereby increasing bone density. This study was carried out to evaluate the efficacy of Zoledronic acid on bone mineral density.
Methods: This study was carried out as a record based cross sectional study among 30 symptomatic adult patients who visited the outpatient department of Orthopedics for a period of two years. Bone mineral density (BMD) parameters assessed using dual-energy X-ray absorptiometry (DEXA) scan were documented for initial period and after six months of intervention. Documentation of intervention with single dose of zoledronic acid 5 mg by intravenous infusion was verified and noted.
Results: There was a significant difference in the mean scores for both femoral neck and lumbar spine with respect to BMD values and T-score values between baseline parameters and values measured after 6 months of Zoledronic acid infusion. The difference was statistically significant (p<0.05).
Conclusions: Single dose of zoledronic acid 5 mg by intravenous infusion was found to be effective in increasing the BMD among individuals suffering from osteopenia and osteoporosis.
References
National Institute of Health Consensus Development Panel on Osteoporosis, Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-95.
National Osteoporosis Foundation. Fast facts on osteoporosis (fact sheet). [Online]. Available from: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed on 4 September 2019.
Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 1999;10(4):259-64.
Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185-94.
Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11(7):556-61.
Lambrinoudaki I, Vlachou S. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clin Interven Ageing. 2008;3(3):445-51.
Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006;119:S25-31.
Package insert. Reclast injection. East Hanover: Novartis Pharmaceuticals Corp; 2010. Available from https://www.pharma.us.novartis.com/sites/ www.pharma.us.novartis.com/files/reclast.pdf? Accessed on 4 September 2019.
Hossain M , Chowdhury IH, Emran MA, Habib AH, Asaduzzamnan AK, Alam M, et al. Effect of single dose intravenous zoledronic acid on bone mineral density in postmenopausal osteoporosis of Bangladeshi women. Bangladesh Med Res Counc Bull. 2010;36(3):747.
Unni J, Garg R, Pawar R. Bone mineral density in women above 40 years. J Midlife Health. 2010;1(1):19-22.
Gandhi A, Shukla A. Evaluation of BMD of women above 40 years of age. J Obstet Gynaecol India. 2005;55:265-7.
Anburajan M, Kumar DA, Sapthagirivasan V. Evaluation of Osteoporosis in Indian Women and Men using Peripheral Dual Energy X-ray Absorptiometry (pDXA). IACSIT Press, Singapore. 2011;5:470-4.
Räkel A, Boucher A, Louis, Ste-Marie G. Role of Zoledronic acid in the prevention and treatment of osteoporosis. Clin Interven Ageing. 2011:6:89-99.
Acha AA, Ostir GV, Markides KS, Ottenbacher KJ. Cognitive status, body mass index and hip fracture in hispanic older adults. J Am Geriatr Soc. 2006;54:1251-5.
Popp AW, Guler S, Lamy O, Senn C, Buffat H, Perrelet R, et al. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res. 2013;28:449-54.
Doggrell SA. Zoledronic Acid Once-yearly: What Role in the prevention of non-vertebral Osteoporotic Fractures? Clinical Medicine Insights: Therapeutics. 2010;2:539-47.
Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long? N Engl J Med. 366;22:2051-3.
Black DM, Delmas PD. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356:1809-22.
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZONPivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-54.
Zhang J, Wang R, Zhao YL, Sun XH, Zhao HX, Lu T, et al. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis. Asian Pacific J Trop Med. 2012;5(9):743-8.
